These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16365461)

  • 21. Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sézary syndrome.
    Introcaso CE; Hess SD; Kamoun M; Ubriani R; Gelfand JM; Rook AH
    J Am Acad Dermatol; 2005 Sep; 53(3):428-34. PubMed ID: 16112348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A clonal CD4-positive T-cell line established from the blood of a patient with Sézary syndrome.
    Abrams JT; Lessin S; Ghosh SK; Ju W; Vonderheid EC; Nowell P; Murphy G; Elfenbein B; DeFreitas E
    J Invest Dermatol; 1991 Jan; 96(1):31-7. PubMed ID: 1987293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new monoclonal antibody (CH-F42) recognizes a CD7- subset of normal T lymphocytes and circulating malignant cells in adult T-cell lymphoma-leukemia and Sézary syndrome.
    Labastide WB; Rana MT; Barker CR
    Blood; 1990 Oct; 76(7):1361-8. PubMed ID: 1698478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Killer cell immunoglobulin-like receptor expression delineates in situ Sézary syndrome lymphocytes.
    Wechsler J; Bagot M; Nikolova M; Parolini S; Martin-Garcia N; Boumsell L; Moretta A; Bensussan A
    J Pathol; 2003 Jan; 199(1):77-83. PubMed ID: 12474229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KIR3DL2/CpG ODN interaction mediates Sézary syndrome malignant T cell apoptosis.
    Ghazi B; Thonnart N; Bagot M; Bensussan A; Marie-Cardine A
    J Invest Dermatol; 2015 Jan; 135(1):229-237. PubMed ID: 25007046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased density of ecto 5' nucleotidase antigen on leukemic T cells from patients with cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma.
    Fukunaga Y; Evans SS; Yamamoto M; Ueda Y; Tamura K; Takakuwa T; Gebhard D; Allopenna J; Demaria S; Clarkson B
    Blood; 1989 Nov; 74(7):2486-92. PubMed ID: 2553165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin.
    Sako N; Schiavon V; Bounfour T; Dessirier V; Ortonne N; Olive D; Ram-Wolff C; Michel L; Sicard H; Marie-Cardine A; Bagot M; Bensussan A; Schmitt C
    Cytometry A; 2014 Oct; 85(10):869-82. PubMed ID: 25044837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenotype of cells involved in mycosis fungoides and Sézary syndrome (blood and skin lesions): immunomorphological study with monoclonal antibodies.
    Schmitt D; Souteyrand P; Brochier J; Czernielewski J; Thivolet J
    Acta Derm Venereol; 1982; 62(3):193-9. PubMed ID: 6179357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
    Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
    J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New developments in Sézary syndrome].
    Caudron A; Marie-Cardine A; Bensussan A; Bagot M
    Ann Dermatol Venereol; 2012 Jan; 139(1):31-40. PubMed ID: 22225740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A restricted clonal T-cell receptor αβ repertoire in Sézary syndrome is indicative of superantigenic stimulation.
    van der Fits L; Sandberg Y; Darzentas N; Zoutman WH; Tielemans D; Wolvers-Tettero IL; Vermeer MH; Langerak AW
    Br J Dermatol; 2011 Jul; 165(1):78-84. PubMed ID: 21410672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Failure of anti-T-cell receptor V beta antibodies to consistently identify a malignant T-cell clone in Sézary syndrome.
    Bigler RD; Boselli CM; Foley B; Vonderheid EC
    Am J Pathol; 1996 Nov; 149(5):1477-83. PubMed ID: 8909237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of CD39 as a Marker for the Circulating Malignant T-Cell Clone of Sézary Syndrome Patients.
    Bensussan A; Janela B; Thonnart N; Bagot M; Musette P; Ginhoux F; Marie-Cardine A
    J Invest Dermatol; 2019 Mar; 139(3):725-728. PubMed ID: 30798854
    [No Abstract]   [Full Text] [Related]  

  • 34. Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sézary syndrome.
    Sokolowska-Wojdylo M; Wenzel J; Gaffal E; Steitz J; Roszkiewicz J; Bieber T; Tüting T
    Clin Exp Dermatol; 2005 Nov; 30(6):702-6. PubMed ID: 16197392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peripheral blood findings in erythrodermic patients: importance for the differential diagnosis of Sézary syndrome.
    Nagler AR; Samimi S; Schaffer A; Vittorio CC; Kim EJ; Rook AH
    J Am Acad Dermatol; 2012 Mar; 66(3):503-8. PubMed ID: 22005074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Candidate counterparts of Sézary cells and adult T-cell lymphoma-leukaemia cells in normal peripheral blood: an ultrastructural study with the immunogold method and monoclonal antibodies.
    Matutes E; Robinson D; O'Brien M; Haynes BF; Zola H; Catovsky D
    Leuk Res; 1983; 7(6):787-801. PubMed ID: 6607389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From single-cell signature to prognostic factors: the case of Sézary syndrome.
    Scala E; Narducci MG; Russo G
    Expert Rev Clin Immunol; 2012 Nov; 8(8):699-701. PubMed ID: 23167680
    [No Abstract]   [Full Text] [Related]  

  • 38. Usefulness of KIR3DL2 to Diagnose, Follow-Up, and Manage the Treatment of Patients with Sézary Syndrome.
    Hurabielle C; Thonnart N; Ram-Wolff C; Sicard H; Bensussan A; Bagot M; Marie-Cardine A
    Clin Cancer Res; 2017 Jul; 23(14):3619-3627. PubMed ID: 28119365
    [No Abstract]   [Full Text] [Related]  

  • 39. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome.
    Yoon JS; Newton SM; Wysocka M; Troxel AB; Hess SD; Richardson SK; Lin JH; Benoit BM; Kasprzycka M; Wasik MA; Rook AH
    J Invest Dermatol; 2008 Feb; 128(2):473-80. PubMed ID: 17713571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Sézary syndrome. Clinical, immunological and proliferative kinetics].
    Marosi L; Hofer F; Schwarzmeier J; Konrad K; Knapp W; Radaskiewicz T
    Acta Med Austriaca; 1979; 6(5):237-40. PubMed ID: 318012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.